Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bacillus Calmette‐Guerin, polysaccharide nucleic acid in the treatment of cutaneous and oral lichen planus

Bacillus Calmette‐Guerin, polysaccharide nucleic acid in the treatment of cutaneous and oral... The aim of this study was to evaluate the safety and efficacy of Bacillus Calmette‐Guerin, polysaccharide nucleic acid (BCG‐PSN) therapy in the treatment of oral and cutaneous LP. Twenty‐four LP patients were included in this study and classified randomly into; Oral LP group (OLP), 11 patients and Cutaneous LP group (CLP), 13 patients. All patients received intradermal injections of BCG‐PSN, twice weekly for three weeks. Patients with complete response were followed up for 3 months. The assessment in OLP was based on the reduction in the treated area, (Reticulation/Erythema/Ulceration) REU scoring system and numerical rating scale (NRS). CLP evaluated by the response to treatment as (complete, partial and no response) and visual analogue scale (VAS). There were highly significant differences in the diminution of lesion areas (p < .006), NRS scores (p < .001), REU score (p < .011), and VAS (p < .001) after treatment. The majority of patients achieved complete response after 3‐week management. The BCG‐PNS is safe and effective in the treatment of oral and cutaneous LP. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Dermatologic Therapy Wiley

Bacillus Calmette‐Guerin, polysaccharide nucleic acid in the treatment of cutaneous and oral lichen planus

Download PDF
4 pages

Loading next page...
 
/lp/wiley/bacillus-calmette-guerin-polysaccharide-nucleic-acid-in-the-treatment-bU2LKlkMgC
Publisher
Wiley
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
1396-0296
eISSN
1529-8019
DOI
10.1111/dth.12591
pmid
29405515
Publisher site
See Article on Publisher Site

Abstract

The aim of this study was to evaluate the safety and efficacy of Bacillus Calmette‐Guerin, polysaccharide nucleic acid (BCG‐PSN) therapy in the treatment of oral and cutaneous LP. Twenty‐four LP patients were included in this study and classified randomly into; Oral LP group (OLP), 11 patients and Cutaneous LP group (CLP), 13 patients. All patients received intradermal injections of BCG‐PSN, twice weekly for three weeks. Patients with complete response were followed up for 3 months. The assessment in OLP was based on the reduction in the treated area, (Reticulation/Erythema/Ulceration) REU scoring system and numerical rating scale (NRS). CLP evaluated by the response to treatment as (complete, partial and no response) and visual analogue scale (VAS). There were highly significant differences in the diminution of lesion areas (p < .006), NRS scores (p < .001), REU score (p < .011), and VAS (p < .001) after treatment. The majority of patients achieved complete response after 3‐week management. The BCG‐PNS is safe and effective in the treatment of oral and cutaneous LP.

Journal

Dermatologic Therapy – Wiley

Published: Jan 1, 2018

Keywords: ; ;

References

  • Immunomodulatory drugs: Oral and systemic adverse effects
    Bascones‐Martinez, A.; Mattila, R.; Gomez‐Font, R.; Meurman, J. H.
  • BCG‐polysaccharide nucleic acid with prednisolone in the treatment of alopecia areata
    Chun, Y. A.
  • Lichen planus – An update
    Gupta, S. B.; Chaudhari, N. D.; Gupta, A.
  • Detection of Mycobacterium tuberculosis in sputum samples by polymerase chain reaction using a simplified procedure
    Kocagoz, T.; Yilmaz, E.; Ozkara, S.
  • Effects of the polysaccharide nucleic acid fraction of bacillus calmetteguérin on the production of interleukin2 and interleukin10 in the peripheral blood lymphocytes of patients with chronic idiopathic urticaria
    Li, N.; Cao, N.; Niu, Y. D.
  • Individualizing treatment and choice of medication in lichen planus: A step by step approach
    Manousaridis, I.; Manousaridis, K.; Peitsch, W. K.; Schneider, S. W.
  • Oral lichen planus: REU scoring system correlates with pain
    Park, H. K.; Hurwitz, S.; Woo, S. B.
  • Ultraviolet‐B treatment for cutaneous lichen planus: our experience with 50 patients
    Pavlotsky, F.; Nathansohn, N.; Kriger, G.; Shpiro, D.; Trau, H.
  • Visual analogue scale: evaluation of the instrument for the assessment of pruritus
    Reich, A.; Heisig, M.; Phan, N.; Taneda, K.; Takamori, K.; Takeuchi, S.; Szepietowski, J.
  • BCG as a new therapeutic and prophylactic agent in patients with severe oral aphthosis
    Sharquie, K. E.; Hayani, R. K.
  • Developments in intralesional therapy for metastatic melanoma
    Sloot, S.; Rashid, O. M.; Sarnaik, A. A.; Zager, J. S.
  • Effect of BCG‐PSN adjuvant therapy on Th1/Th2 immune response in bronchial asthma children
    Wang, H.
  • The efficacy of topical intralesional BCG‐PSN injection in the treatment of erosive oral lichen planus: a randomized controlled trial
    Xiong, C.; Li, Q.; Lin, M.; Li, X.; Meng, W.; Wu, Y.; Zhou, G.
  • Treatment of BCG polysaccharide nucleic acid combined with CO2 laser reduces Th17 cells and their related cytokines in cutaneous lesion of vitiligo patients
    Zhan, L.; Xiong, X.; Wang, L.
  • Effects of BCG‐PSN on serum levels of IL‐4 and IL‐12 in patients with condyloma acuminata
    Zuo, C.; Huang, J. H.; Liao, Z. H.